Multiple Myeloma Clinical Trials

A listing of 183 Multiple Myeloma clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Multiple Myeloma

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 183 active clinical trials seeking participants for Multiple Myeloma research studies. The states with the highest number of trials for Multiple Myeloma participants are California, New York, Ohio and Texas.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Chronic Cough Research Study

Recruiting

Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!

Conditions:

Chronic Cough

Refractory or Unexplained Chronic Cough

Cough

Asthma

Sinusitis

Learn More

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

Featured Trial

Stroke Clinical Study

Recruiting

A clinical study for people that suffer with Stroke

Conditions:

Stroke

Learn More

A Study of Talquetamab for People with Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy

NCT06066346

Recruiting

The researchers are doing this study to find out whether talquetamab is an effective treatment after BCMA CAR Tcell therapy for people with relapsed or refractory multiple myeloma. All participants in this study will have already received the BCMA CAR T-cell therapy ide-cel for their disease.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/30/2025

Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +6 locations

Conditions: Multiple Myeloma

Learn More ›

Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma

NCT02291848

Recruiting

This study is for patients that have a cancer called Multiple Myeloma, monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma (SM). MGUS and SM have tumor cells that possess nearly identical properties to the cancer cells seen in patients with multiple myeloma. The investigators would like to target proteins that are expressed by these cells using the patient's own immune cells known as T lymphocytes.This research study uses special immune system cells called tumor asso... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/29/2025

Locations: Harris Health Ben Taub Hospital, Houston, Texas +2 locations

Conditions: Multiple Myeloma

Learn More ›

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

NCT01838512

Recruiting

The purpose of this study is to assess the clinical effectiveness of all approved multiple myeloma (MM) therapies in the newly-diagnosed (NDMM) and the relapsed/refractory MM (RRMM) settings in real-world clinical practice.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/28/2025

Locations: Local Institution, Birmingham, Alabama +197 locations

Local Institution, Birmingham, Alabama

Local Institution - 0021, Birmingham, Alabama

Local Institution - 0013, Muscle Shoals, Alabama

Local Institute, Goodyear, Arizona

Local Institution - 0023, Anaheim, California

Local Institution, Anaheim, California

Local Institution - 0045, Burbank, California

Local Institution, Corona, California

Local Institution - 0048, Downey, California

Local Institution - 0052, Fountain Valley, California

Local Institute, Los Angeles, California

Local Institute, Santa Rosa, California

Local Institution - 0051, Santa Rosa, California

Local Institution - 0057, Washington, District of Columbia

Florida Cancer Specialists & Research Institute, Brooksville, Florida

Local Institution, Brooksville, Florida

Local Institution - 0044, Fort Lauderdale, Florida

Local Institution - 0017, Jacksonville, Florida

Local Institution, Jacksonville, Florida

Local Institution - 0046, Savannah, Georgia

Local Institute, Valdosta, Georgia

Local Institution - 0047, Valdosta, Georgia

Local Institution, Skokie, Illinois

Local Institution - 0041, Springfield, Illinois

Local Institution - 0012, Urbana, Illinois

Local Institution - 0058, Anderson, Indiana

Local Institution - 0011, Indianapolis, Indiana

Local Institution, Indianapolis, Indiana

Local Institution - 0061, Des Moines, Iowa

Local Institute, Sioux City, Iowa

Local Institution - 0018, Sioux City, Iowa

Local Institution - 0062, Lexington, Kentucky

Local Institution - 0064, London, Kentucky

Local Institute, Louisville, Kentucky

Local Institution - 0042, Louisville, Kentucky

Cancer Center of Acadiana at Lafayette General Health, Lafayette, Louisiana

Local Institution, Lafayette, Louisiana

Local Institution - 0009, Shreveport, Louisiana

Local Institution, Shreveport, Louisiana

Local Institution, Minneapolis, Minnesota

Local Institution - 0030, Woodbury, Minnesota

Local Institution - 0059, Jackson, Mississippi

Local Institute, Southaven, Mississippi

Local Institute, Kansas City, Missouri

Local Institution - 0050, Kansas City, Missouri

Local Institution - 0037, Missoula, Missouri

Local Institute, Saint Joseph, Missouri

Local Institution - 0015, Saint Louis, Missouri

Local Institution, Saint Louis, Missouri

Local Institution - 0020, Springfield, Missouri

Local Institution, Springfield, Missouri

Local Institute, Missoula, Montana

Local Institution - 0060, Lincoln, Nebraska

Local Institute, Omaha, Nebraska

Local Institution - 0024, Omaha, Nebraska

Local Institution - 008, Does Not Exist, New Jersey

Generic Country - Canada, No City Provided, New Jersey

Generic Country - France, No City Provided, New Jersey

Generic Country - Germany, No City Provided, New Jersey

Generic Country - Italy, No City Provided, New Jersey

Generic Country - UK, No City Provided, New Jersey

Generic Country - USA, No City Provided, New Jersey

Local Institution - 0049, Stony Brook, New York

Local Institute, Cary, North Carolina

Local Institution - 0033, Cary, North Carolina

Local Institution - 0010, Gastonia, North Carolina

Local Institution, Gastonia, North Carolina

Local Institute, Canton, Ohio

Local Institution - 0022, Canton, Ohio

Local Institute, Cleveland, Ohio

Local Institution - 0019, Cleveland, Ohio

Local Institute, Tulsa, Oklahoma

Tulsa Cancer Institute PLLC, Tulsa, Oklahoma

Local Institute, Portland, Oregon

Local Institute, Pottstown, Pennsylvania

Local Institution - 0043, Pottstown, Pennsylvania

Local Institute, Charleston, South Carolina

Local Institution - 0016, Charleston, South Carolina

Local Institute, Knoxville, Tennessee

Local Institution - 0038, Knoxville, Tennessee

Local Institution - 0035, Memphis, Tennessee

Local Institution, Memphis, Tennessee

Local Institute, Amarillo, Texas

Local Institution - 0029, Amarillo, Texas

Local Institution - 0063, Bryan, Texas

Local Institute, Corpus Christi, Texas

Local Institute, Dallas, Texas

Local Institution - 0025, Dallas, Texas

Local Institute, Dallas, Texas

Local Institution - 0014, Dallas, Texas

Local Institution - 0032, Garland, Texas

Local Institute, San Antonio, Texas

Local Institution - 0027, San Antonio, Texas

Local Institute, Sherman, Texas

Local Institution - 0028, Sherman, Texas

Local Institute, Seattle, Washington

Local Institution - 0039, Seattle, Washington

Local Institute, Spokane, Washington

Local Institution - 0026, Spokane, Washington

Local Institute, Yakima, Washington

Local Institution - 0031, Yakima, Washington

Local Institution - 0065, Toronto, Ontario

Local Institute, Toronto, Ontario

Local Institution - 0066, Toronto, Ontario

Local Institute, Weston, Ontario

Local Institute, Blois, Not set

Local Institution - 0106, Cannes Cedex, Not set

Local Institution - 0099, Chalon sur Saone, Not set

Local Institute, Chalon sur Saone, Not set

Local Institute, La Roche sur Yon, Not set

Local Institution - 0100, La Roche-sur-yon Cedex 9, Not set

Local Institution - 0104, Limoges, Not set

Local Institute, Limoges, Not set

Local Institution - 0105, Meaux, Not set

Local Institute, Meaux, Not set

Local Institution - 0102, Nantes, Not set

Local Institute, Nantes, Not set

Local Institution - 0101, Perigueux, Not set

Local Institute, Rennes, Not set

Local Institution - 0103, Rennes, Not set

Local Institute, Heidelberg, Baden-Württemberg

Local Institute, Hamm, Nordrhein-Westfalen

Local Institute, Aschaffenburg, Not set

Local Institution - 0072, Aschaffenburg, Not set

Local Institute, Berlin, Not set

Local Institution - 0068, Berlin, Not set

Local Institution - 0081, Bielefeld, Not set

Local Institution, Bochum, Not set

Local Institute, Dresden, Not set

Local Institution - 0069, Dresden, Not set

Local Institution - 0082, Dresden, Not set

Local Institution - 0077, Frankfurt-oder, Not set

Local Institution - 0084, Gelsenkirchen, Not set

Local Institution - 0089, Goslar, Not set

Local Institution - 0070, Hamm, Not set

Local Institution - 0071, Heidelberg, Not set

Local Institution - 0088, Kiel, Not set

Local Institution - 0087, Köln, Not set

Local Institution - 0076, Ludwigsburg, Not set

Local Institute, Magdeburg, Not set

Local Institution - 0067, Magdeburg, Not set

Local Institution - 0073, Muenchen, Not set

Local Institution - 0079, Mutlangen, Not set

Local Institute, München, Not set

Local Institution - 0080, Oldenburg, Not set

Local Institution - 0075, Reutlingen, Not set

Local Institution - 0074, Rostock, Not set

Local Institution - 0086, Rostock, Not set

Local Institute, Rostock, Not set

Local Institution - 0078, Traunstein, Not set

Local Institution - 0085, Wiesbaden, Not set

Local Institute, Pesaro, Pesaro E Urbino

Local Institute, Ancona, Not set

Local Institution - 0108, Ancona, Not set

Local Institute, Ancona, Not set

Local Institution - 0119, Cagliari, Not set

Local Institute, Cagliari, Not set

Local Institution - 0111, Firenze, Not set

Local Institute, Firenze, Not set

Local Institute, Lecce, Not set

Local Institution - 0113, Lecce, Not set

Local Institution - 0124, Messina, Not set

Local Institution - 0120, Messina, Not set

Local Institute, Milano, Not set

Local Institution - 0116, Milano, Not set

Local Institute, Napoli, Not set

Local Institution - 0114, Napoli, Not set

Local Institution - 0115, Pesaro, Not set

Local Institution - 0121, Pescara, Not set

Local Institute, Roma, Not set

Local Institution - 0109, Roma, Not set

Local Institution - 0110, Roma, Not set

Local Institution - 0118, Roma, Not set

Local Institution, Roma, Not set

Local Institution - 0122, San Giovanni Rotondo (FG), Not set

Local Institution - 0107, Terni, Not set

Local Institute, Terni, Not set

Local Institute, Torino, Not set

Local Institution - 0112, Torino, Not set

Local Institute, Vicenza, Not set

Local Institution - 0117, Vicenza, Not set

Local Institute, Truro, Cornwall

Local Institution - 0098, Harrow, Greater London

Local Institute, Leeds, Not set

Local Institution - 0092, Leeds, Not set

Local Institution - 0091, Liverpool, Not set

Local Institution, Liverpool, Not set

Local Institution - 0097, Manchester, Not set

Local Institute, Nottingham, Not set

Local Institution - 0095, Nottingham, Not set

Local Institute, Stafford, Not set

Local Institution - 0096, Stafford, Not set

Local Institute, Swansea, Not set

Local Institution - 0093, Swansea, Not set

Local Institution - 0094, Truro, Not set

Conditions: Multiple Myeloma

Learn More ›

Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy

NCT04975555

Recruiting

This study will evaluate the use of siltuximab to decrease the severity of cytokine release syndrome (CRS) and immune effector cell-associated neurological syndrome (ICANS) in patients who will receive chimeric antigen receptor (CAR) T-cell therapy for the treatment of hematological malignancies.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/24/2025

Locations: University of Alabama at Birmingham, Birmingham, Alabama

Conditions: Cytokine Release Syndrome, ICANS, Lymphoma, Non-Hodgkin, Multiple Myeloma, Acute Lymphoblastic Leukemia

Learn More ›

DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics

NCT06296368

Recruiting

The purpose of this study is to evaluate whether a novel decision support tool called PRIME (Preference Reporting to Improve Management and Experience), which combines values-elicitation with tailored feedback to patients and providers, improves patient-reported values-concordance of initial treatment decisions compared to usual care.

Gender:

ALL

Ages:

60 years and above

Trial Updated:

01/23/2025

Locations: Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill, North Carolina

Conditions: Hematologic Malignancies, Lymphoma, Multiple Myeloma, Leukemia, Blood Cancers

Learn More ›

Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

NCT05706766

Recruiting

The goal of this research study is to investigate whether a virtual, home-based, prehabilitation aerobic and resistance exercise (PARE) training program implemented 8 weeks prior to receiving autologous stem cell transplant (ASCT) for multiple myeloma participants will improve muscular strength, physical capacity, patient reported outcomes, and cardiometabolic health outcomes. The names of the study interventions involved in this study are: * Prehabilitative aerobic and resistance exercise (PA... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/23/2025

Locations: Dana Farber Cancer Institute, Boston, Massachusetts +1 locations

Conditions: Multiple Myeloma, Stem Cell Transplant Complications

Learn More ›

Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients with Renal Insufficiency

NCT04240054

Recruiting

This is a single-arm, open-label phase II study with a safety lead-in phase.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/22/2025

Locations: Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin

Conditions: Multiple Myeloma

Learn More ›

Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders

NCT00582621

Recruiting

The purpose of this study is to better understand the genetic causes of Hodgkin's disease (a kind of lymphoma) and non-Hodgkin's lymphoma, as well as multiple myeloma, leukemia, and related diseases. The doctors have identified the patient because 1) they have had a lymphoproliferative disorder such as lymphoma, leukemia, or multiple myeloma, and have a family member with one of these disorders or 2) they are a member of a family with a lymphoproliferative disorder, including Hodgkin's disease a... Read More

Gender:

ALL

Ages:

All

Trial Updated:

01/21/2025

Locations: Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey +5 locations

Conditions: Lymphoma, Leukemia, Multiple Myeloma, Colon Cancer, Renal Cancer

Learn More ›

Iberdomide and Daratumumab As Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma

NCT06107738

Recruiting

The goal of this phase 2 clinical trial is to learn if patients with Multiple Myeloma who are minimal residual disease positive after initial therapy (including an autologous stem cell transplant \[ASCT\]) will benefit from maintenance therapy with Iberdomide and subcutaneous (SC) Daratumumab. The main questions it aims to answer are: * Assess if giving Iberdomide and the SC Daratumumab in the maintenance setting is an effective treatment and warrants further investigation in patients with residual disease * Is giving Iberdomide and SC Daratumumab maintenance post ASCT a safe option Participants will: * provide informed consent and complete screening assessments for eligibility within 28 days of starting treatment * Screening assessments include specific laboratory tests, a medical history assessment and a physical examination (including temperature, pulse, blood pressure, respirations, height and weight), an assessment of your heart function, a breathing test, cancer imaging, a bone marrow biopsy, minimal residual disease testing (MRD) and a questionnaire * If eligible, patients will start treatment with Iberdomide (1.0 mg on day 1-21 of each 28 day cycle, with an increase to 1.3 mg on Cycle 4 if the 1.0 mg dose was tolerated, to a maximum of 26 cycles or progressive disease, whichever is first) and SC Daratumumab (1800 mg SC on days 1, 8, 15 and 22 of cycle 1 and 2, then 1800 mg SC on Day 1 and 15 of cycle 3-6 and 1800 mg SC on Day 1 for cycles 7-26 to a maximum of 26 cycles or progressive disease, whichever is first) * while receiving treatment on study, physical exams (including temperature, pulse, blood pressure, respirations, height and weight), toxicity assessments, laboratory assessments and questionnaires will be done at various times over the course of the 26 cycles * an MRD assessment is required at 6, 12 and 24 months after starting treatment * End of treatment will occur once 26 cycles are completed, or cancer has progressed whichever comes first. At that time, specific laboratory tests, a physical examination (including temperature, pulse, blood pressure, respirations, height and weight), cancer imaging, a bone marrow biopsy and minimal residual disease testing (MRD) will occur. Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/07/2025

Locations: Karmanos Cancer Institute, Detroit, Michigan +1 locations

Conditions: Multiple Myeloma

Learn More ›

Collection of Samples and Clinical Data From Patients With Amyloid Diseases

NCT00898235

Recruiting

RATIONALE: Collecting and storing samples of blood, urine, tissue and data from patients with amyloid diseases to test in the laboratory may help the study of this disease in the future. PURPOSE: This research study is collecting samples from patients with amyloid diseases

Gender:

ALL

Ages:

18 years and above

Trial Updated:

12/26/2024

Locations: Boston University Cancer Research Center, Boston, Massachusetts

Conditions: Multiple Myeloma

Learn More ›

Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function

NCT06623630

Recruiting

Treatment for relapsed/refractory multiple myeloma continues to evolve with the approval of highly effective anti-BCMA CAR T therapies in recent years. However, despite the high prevalence of renal insufficiency in this population, pivotal clinical trials have excluded patients with impaired renal function, leading to an urgent, unmet clinical need to develop safe and effective lymphodepleting regimens prior to CAR T administration for this population. In addition, renal insufficiency is linked... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

12/21/2024

Locations: Washington University School of Medicine, Saint Louis, Missouri

Conditions: Multiple Myeloma

Learn More ›

Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma

NCT06209606

Recruiting

This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of ruxolitinib, steroids and lenalidomide among MM patients who currently show progressive disease using BCMA to test progression.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

12/12/2024

Locations: Berenson Cancer Center, West Hollywood, California

Conditions: Multiple Myeloma

Learn More ›